What’s behind Novo Nordisk’s success? Can a company get too big?

Staci West 12/09/2023 in Europe

Novo Nordisk, a leading global healthcare company, now has a market capitalisation that is bigger than the GDP of its home country Denmark. Mark Nichols, co-manager of the Jupiter European fund, tells us how the company has remained so successful for so many years, and answers the question “can a company get too big?”.

Watch the full interview with Mark Nichols highlighting the opportunities in Europe today

This article is provided for information only. The views of the author and any people quoted are their own and do not constitute financial advice. The content is not intended to be a personal recommendation to buy or sell any fund or trust, or to adopt a particular investment strategy. However, the knowledge that professional analysts have analysed a fund or trust in depth before assigning them a rating can be a valuable additional filter for anyone looking to make their own decisions. Past performance is not a reliable guide to future returns. Market and exchange-rate movements may cause the value of investments to go down as well as up. Yields will fluctuate and so income from investments is variable and not guaranteed. You may not get back the amount originally invested. Tax treatment depends of your individual circumstances and may be subject to change in the future. If you are unsure about the suitability of any investment you should seek professional advice. Whilst FundCalibre provides product information, guidance and fund research we cannot know which of these products or funds, if any, are suitable for your particular circumstances and must leave that judgement to you. Before you make any investment decision, make sure you’re comfortable and fully understand the risks. Further information can be found on Elite Rated funds by simply clicking on the name highlighted in the article.